Exceptional growth for Venture Capital Deals in radiopharmaceutical companies in 2023

8 Dec 2023 | Misc, Radiopharmaceutical Therapy

GlobalData Reports that Venture Capital Deals in radiopharmaceutical companies have grown 550% to $408m in 2023 GlobalData reports that venture capital deals in radiopharmaceuticals have grown by 550% this year totalling $408m. It was only back in 2017 when the level...

Dr Lena Unterrainer presents data on [Ga-68]EMP-100 at EANM 2023

12 Sep 2023 | [Ga-68]EMP-100, Collaborations, Radiopharmaceutical Therapy

Dr Lena Unterrainer presented [Ga-68]EMP-100 as one of the “dark horses of theranostics” and showed the data of [Ga-68]EMP-100 in...

Results published by Investigator on non-invasive assessment of c-MET expression in non-small cell lung cancer

1 Mar 2023 | [Ga-68]EMP-100, Collaborations

A case of a 56-year-old female former smoker with stage IV EGFR mutation-positive NSCLC (lymphogenic, pulmonary, hepatic, and cerebral metastases is presented. Stage: cT3, cN3, cM1b) and concomitant MET exon 14 skipping mutation. After multiple pretreatments including...

Christophe Portal is Promoted to CSO for Edinburgh Molecular Imaging

1 Mar 2023 | Corporate

Dr Christophe Portal has been appointed as Chief Scientific Officer. Christophe has 15 years of industrial experience in the research and development of peptide and peptide like molecules for imaging and therapy. He started his career working for a biotechnology...

Alex Gibson is Promoted to CEO for Edinburgh Molecular Imaging

1 Mar 2023 | Corporate

Dr Alex Gibson has been appointed as Chief Executive Officer. Alex has over 25 years of experience in the radiopharmaceutical industry starting as a radiochemist with Amersham  (now part of GE Healthcare). Following several roles within imaging pharmaceutical R&D,...